Aadi Bioscience (NASDAQ:AADI) Announces Earnings Results

Aadi Bioscience (NASDAQ:AADI) released its earnings results on Wednesday. The company reported ($0.54) earnings per share for the quarter, topping the consensus estimate of ($0.71) by $0.17, Zacks reports. The business had revenue of $6.18 million during the quarter, compared to the consensus estimate of $6.33 million. Aadi Bioscience had a negative return on equity of 61.83% and a negative net margin of 288.72%. During the same period last year, the company earned ($0.67) earnings per share.

Aadi Bioscience Stock Performance

Shares of NASDAQ AADI remained flat at $1.35 during trading hours on Thursday. The company had a trading volume of 250,271 shares, compared to its average volume of 286,884. Aadi Bioscience has a 12-month low of $1.21 and a 12-month high of $7.24. The firm has a market cap of $33.15 million, a price-to-earnings ratio of -0.53 and a beta of 0.69. The company has a 50-day moving average price of $1.57 and a two-hundred day moving average price of $1.82.

Insiders Place Their Bets

In other Aadi Bioscience news, Chairman Neil Desai sold 31,348 shares of the company’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $1.45, for a total value of $45,454.60. Following the completion of the sale, the chairman now directly owns 1,260,195 shares in the company, valued at approximately $1,827,282.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders have sold 52,415 shares of company stock worth $76,151 in the last ninety days. 37.30% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Aadi Bioscience in a research note on Tuesday, May 14th.

Aadi Bioscience Company Profile

Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.